- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | OS Therapies stock surges after positive FDA feedback on OST-HER2 | 1 | Investing.com | ||
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| Di | OS Therapies-Aktie steigt nach positiver FDA-Rückmeldung zu OST-HER2/n | 1 | Investing.com Deutsch | ||
| Di | OS Therapies erhält positives FDA-Feedback für Osteosarkom-Behandlung | 1 | Investing.com Deutsch | ||
| Di | OS Therapies receives positive FDA feedback for osteosarcoma treatment | 2 | Investing.com | ||
| Di | OS Therapies Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 11.06. | OS Therapies Taps EVERSANA To Launch First New Pediatric Osteosarcoma Treatment In 40 Years | 1 | RTTNews | ||
| 10.06. | OS Therapies kooperiert mit EVERSANA für Krebsmedikamenten-Markteinführung | 1 | Investing.com Deutsch | ||
| 06.06. | OS Therapies Submits Request For RMAT Designation For OST-HER2 | 1 | RTTNews | ||
| 06.06. | OS Therapies seeks FDA regenerative therapy tag for cancer drug | 1 | Investing.com | ||
| 23.05. | OS Therapies Inc - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 16.05. | OS Therapies GAAP EPS of -$0.18 misses by $0.11 | 2 | Seeking Alpha | ||
| 16.05. | OS Therapies Launches Subsidiary To Commercialize Canine Osteosarcoma Treatment | 1 | RTTNews | ||
| 07.05. | OS Therapies secures patent for cancer immunotherapy tech | 1 | Investing.com | ||
| 07.05. | OS Therapies sichert Patent für Krebsimmuntherapie-Technologie | - | Investing.com Deutsch | ||
| 10.04. | OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans | 285 | Newsfile | Yet to be published data from clinical study combining OST-HER2 with palliative radiation in dogs with unresected, primary osteosarcoma shows clinical and radiographic arrest of the primary tumor,... ► Artikel lesen | |
| 09.04. | OS Therapies Inc - 8-K, Current Report | 5 | SEC Filings | ||
| 09.04. | OS Therapies übernimmt Immuntherapie-Vermögenswerte von Advaxis | 1 | Investing.com Deutsch | ||
| 09.04. | OS Therapies acquires Advaxis Immunotherapies assets | 1 | Investing.com | ||
| 31.03. | OS Therapies Inc - 10-K, Annual Report | - | SEC Filings | ||
| 31.03. | OS Therapies macht Fortschritte mit OST-HER2 für Osteosarkom | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 40,600 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen | |
| IMMUNIC | 0,602 | +1,01 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,250 | +1,81 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort | -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. -... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 13,330 | -7,49 % | EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics | CANBERA (dpa-AFX) - Biotechnology firm CSL Ltd. (CSL.AX, CMXHF.PK) and sa-mRNA pioneer Arcturus Therapeutics Ltd. (ARCT) announced Friday that the European Commission has granted marketing authorization... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,290 | -4,44 % | Protalix BioTherapeutics, Inc. - 8-K, Current Report | ||
| SCILEX | 6,030 | +14,20 % | Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May ... | ||
| MEIRAGTX | 5,600 | +1,82 % | MeiraGTx erhält britische Genehmigungen für Hologen-Transaktion | ||
| INVIVYD | 0,744 | -6,83 % | Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection | Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mild to moderate... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 6,795 | +14,39 % | Unicycive Therapeutics, Inc. Announces Reverse Stock Split | LOS ALTOS, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today... ► Artikel lesen | |
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report |
OS THERAPIES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,010 (+0,55 %) liegt der Kurs bei 1,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.